Compound reference

Petrelintide

A long-acting amylin analog in clinical development for obesity; it remains investigational and is not approved.

Updated October 2026 · 3 minute read
This page is an educational reference, not medical advice. Petrelintide is an investigational drug and is not approved by the FDA.

What it is

Petrelintide is a long-acting amylin analog developed for obesity. Amylin is a hormone co-secreted with insulin from the pancreas that slows gastric emptying and promotes meal termination through central (brain-based) mechanisms. Amylin analogs promote satiety, the feeling of fullness, through a mechanism distinct from GLP-1 and other incretin-based treatments.

In the PeptidesAI encyclopedia, petrelintide is categorized under weight management. It remains investigational: the human data described on this page come from phase 1 and phase 2 trials.

How it's thought to work

Petrelintide mimics amylin, the pancreatic hormone co-secreted with insulin, which slows gastric emptying and promotes satiety. The authors of the phase 2 trial describe this as a mechanism of action distinct from incretin-based treatments.

What the research says

In ZUPREME-1, a phase 2 trial in 493 randomized adults with obesity and without type 2 diabetes, the mean change in body weight after 28 weeks ranged from -7.9% to -9.8% across the five petrelintide groups, compared with -1.7% on placebo, and body weight continued to decline to week 42, with reductions of up to -10.7%.

In two phase 1 trials, petrelintide had a half-life of about 10 days and reduced body weight by up to 8.6% after 16 weeks.

Reported side effects

In the phase 2 trial, the most common adverse event with petrelintide was nausea (20% of participants versus 6% on placebo), predominantly mild and occurring during dose escalation. Vomiting (3% versus 6%), diarrhea (7% versus 7%) and constipation (7% versus 4%) were infrequent. In the phase 1 trials, most gastrointestinal adverse events were mild and none was serious or severe.

Reconstitution

Petrelintide is supplied as a lyophilized (freeze-dried) powder and is typically reconstituted with bacteriostatic (BAC) water before use. It commonly comes in 5 mg and 10 mg vials. The amount of peptide in the vial is fixed; the water added only changes how concentrated the solution is.

Worked example. A 5 mg vial is 5,000 mcg. Reconstituted with 1 mL of BAC water, that works out to 5,000 mcg ÷ 1 mL = 5,000 mcg/mL. On a U-100 insulin syringe, where each unit is 0.01 mL, each unit holds 5,000 × 0.01 = 50 mcg. Use the peptide reconstitution calculator to work out the concentration and units for any vial size and water volume.

Important notes

Petrelintide is an investigational compound and is not FDA-approved. Material sold as a research chemical is not a regulated medicine, so its quality and purity are not independently verified.

Sources

  1. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.. Garvey WT et al. Lancet Diabetes Endocrinol, 2026. Human trial
  2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.. Brændholt Olsen M et al. Diabetes Obes Metab, 2026. Human trial
  3. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.. Alhazmi A et al. Diabetes Obes Metab, 2026. Review

How we choose and check sources

Frequently asked questions

These questions cover the same ground as the sections above, in a shorter format.

What is petrelintide?

A long-acting amylin analog in clinical development for obesity. It is investigational and not FDA-approved.

How is petrelintide thought to work?

It mimics amylin, a hormone co-secreted with insulin that slows gastric emptying and promotes satiety, through a mechanism distinct from GLP-1.

What does the research on petrelintide say?

A phase 2 trial in 493 adults with obesity reported mean body weight changes of -7.9% to -9.8% at 28 weeks across petrelintide groups versus -1.7% on placebo.

What are the reported side effects of petrelintide?

Mainly nausea, predominantly mild and during dose escalation (20% versus 6% on placebo); vomiting, diarrhea and constipation were infrequent.

How much is one unit from a 5 mg Petrelintide vial?

With 1 mL of BAC water, a 5 mg vial is 5,000 mcg/mL, so one unit on a U-100 syringe (0.01 mL) holds 50 mcg.

The full entry, plus the calculator

The PeptidesAI app has the complete encyclopedia entry for Petrelintide — one of 70 compounds covered — plus the reconstitution calculator, a dose log and reminders. Free to download on iPhone.

Download on the App Store

Related